Hikma PHarmaceuticals Plc annual rePort 2013 NOTES TO THE CONSOLIDATED FINANCIALSTATEMENTS Continued 4. segmental rePorting for management purposes, the group is currently organised into three principal operating divisions Branded, injectables and generics.
these divisions are the basis on which the group reports its segmental information.
the group discloses underlying operating profit as the measure of segmental result, as this is the measure used in the decision-making andresource allocation process of the chief operating decision-maker, who is the groups chief executive officer.
information regarding the groups operating segments is reported below.
the following is an analysis of the groups revenue and results by reportable segment in 2013: branded injectables Generics others Group year ended 31 december 2013 $m $m $m $m $m revenue 554 536 268 7 1,365 cost of sales 278 254 62 7 601 Gross profit 276 282 206 764 Adjusted segment result 135 166 166 9 458 exceptional items: severance costs 1 1 plant remediation costs 24 24 impairment losses 6 4 10 other claims provisions 11 11 intangible amortisation 10 5 15 segment result 124 155 127 9 397 unallocated corporate expenses 45 Adjusted operating profit 413 operating profit 352 associated companies share of results 3 exceptional impairment of investment 16 finance income 2 finance expense 37 profit before tax 298 tax 82 profit for the year 216 attributable to: non-controlling interest 4 equity holders of the parent 212 216 segment result is defined as operating profit for each segment.
intangible amortisation comprises the amortisation on intangible assets other than software others mainly comprises arab medical containers ltd, international Pharmaceutical research center ltd and the chemicals division of Hikma Pharmaceuticals ltd Jordan.
unallocated corporate expenses are primarily made up of employee costs, office costs, professional fees, donations, and travel expenses.
140 financial statements 4. segmental rePorting continueD corporate branded injectables Generics and others Group segment assets and liabilities 2013 $m $m $m $m $m additions to property, plant and equipment cost 25 31 10 66 acquisition of subsidiaries property, plant and equipment net book value 6 6 additions to intangible assets 3 13 2 18 intangible assets arising on acquisition 20 20 total property, plant and equipment and intangible assets net book value 519 314 51 6 890 depreciation and impairment 22 17 8 2 49 amortisation and impairment including software 10 12 4 26 investment in associates and joint ventures 22 22 Balance sheet total assets 1,138 592 141 58 1,929 total liabilities 551 259 25 60 895 the following is an analysis of the groups revenue and results by reportable segment in 2012: branded injectables Generics others Group year ended 31 december 2012 $m $m $m $m $m revenue 529 470 104 6 1,109 cost of sales 272 251 78 4 605 Gross profit 257 219 26 2 504 Adjusted segment result 124 123 14 3 230 exceptional items: integration-related expenses 1 2 3 severance expenses 3 1 4 plant remediation costs 7 7 intangible amortisation 9 4 13 segment result 111 116 21 3 203 unallocated corporate expenses 36 Adjusted operating profit 194 operating profit 167 share of results of associated companies 1 finance income 1 finance expense 38 other expense net 1 profit before tax 132 tax 25 profit for the year 107 attributable to: non-controlling interest 7 equity holders of the parent 100 107 segment result is defined as operating profit for each segment.
intangible amortisation comprises the amortisation of intangible assets other than software others mainly comprise arab medical containers ltd, international Pharmaceutical research center ltd and the chemicals division of Hikma Pharmaceuticals ltd Jordan.
unallocated corporate expenses are primarily made up of employee costs, office costs, professional fees, donations and travel expenses.
141 Hikma PHarmaceuticals Plc annual rePort 2013 NOTES TO THE CONSOLIDATED FINANCIALSTATEMENTS Continued 4. segmental rePorting continueD corporate and branded injectables Generics others Group segment assets and liabilities 2012 $m $m $m $m $m additions to property, plant and equipment cost 26 17 5 2 50 additions to intangible assets 2 35 7 44 total property, plant and equipment and intangible assets net book value 504 282 61 6 853 depreciation 21 13 7 2 43 amortisation including software 10 6 16 investment in associates and joint ventures 38 38 Balance sheet total assets 1,050 481 135 64 1,730 total liabilities 574 252 6 50 882 the following table provides an analysis of the groups sales by geographical market, irrespective of the origin of the goods services: 2013 2012 $m $m middle east and north africa 638 619 united states 631 400 europe and rest of the World 89 81 united kingdom 7 9 1,365 1,109 the top selling markets were as below: 2013 2012 $m $m united states 631 400 saudi arabia 132 125 algeria 125 121 888 646 generics revenue was $268 million 2012: $104 million.
this mostly reflects very strong sales of doxycycline and includes only a limited contribution from the rest of our portfolio.
included in revenues arising from the generics and injectables segments are revenues of approximately $172 million 2012: 86 million which arose from the groups largest customer which is located in the united states.
in prior periods, the groups largest customer was located in saudi arabia, the Branded and injectables segments included revenue arising from this customer of $101 million and $104 million for the periods ended 31 December 2013 and 31 December 2012 respectively.
the following is an analysis of the total non-current assets excluding deferred tax and financial instruments and an analysis of total assets bythe geographical area in which the assets are located: total non-current assets excluding deferred tax and financialinstruments as at 31 december total assets as at 31 december 2013 2012 2013 2012 $m $m $m $m middle east and north africa 624 601 1,255 1,157 europe 156 145 217 191 united states 163 156 437 373 united kingdom 3 20 9 946 902 1,929 1,730 142
